EASDec 2016
Manchester UK 23rd to 25th June 2016
Draft Full Programme

Pre-EASDec meetings:

Wednesday, 22nd June 2016 – Thursday, 23rd June 2016
EUROCONDOR General Assembly (by invitation only)
Screening for Diabetic Retinopathy in Europe – National Representatives Meeting (by invitation only)

EASDEC 2016 Programme

Thursday, 23rd June 2016, Citylabs, Nelson St, Manchester M13 9NQ
5.15 - 6.30: Satellite Symposium: Diabetic eye screening and eye care around the world
5.15 - 6.00: Diabetes care around the World: The Barometer Project
6.00 - 6.15: Summary of the European screening symposium
6.15 - 6.30: Diabetic care in Africa, Caribbean, Indonesia/Sri Lanka

The official programme of EASDec starts:
6.30 – 8.00: Opening ceremony with light refreshments

Friday, 24th June 2016, Renold Building, Room C15, University of Manchester
8.30 - 9.00: Registration
8.50 - Introduction and welcome by Professor Simon Harding

Session 1: Treatment of diabetic macular oedema
9.00 - 9.30: Keynote speaker: Professor Albert Augustin, Germany: The EARLY Study and the use of steroids in the treatment of diabetic macular oedema
9.30 - 9.45: Subramani, S (UK): Intravitreal ranibizumab for diabetic macular oedema - a retrospective review of 12 month follow up data at The Manchester Royal Eye Hospital (MREH), UK
9.45 - 10.00: Kelly, SP (UK): Real-world outcomes with ranibizumab treatment in diabetic macular oedema patients with poor baseline visual acuity: 1-year results from the LUMINOUS™ study
10.00 - 10.15: The winner of the Professor Anne Katrin Sjolie Prize for the best abstract from a trainee: Gerendas, BS (Austria): Prognostic factors in the treatment of diabetic macular edema (DME) using aflibercept, ranibizumab and bevacizumab (DRCR.net protocol T)
10.15 - 10-30: Keynote speaker: Dr. Paul Bishop, UK: Metabolomics and metallomics provide novel insights into the molecular pathology of diabetic retinopathy
10.30 - 11.15: Coffee/tea, exhibitions

Session 2: Diabetic retinopathy screening and visual function
11.15 - 11.30: Thornling-Schmidt, H (Denmark): Nurse-led eye screening in a specialist diabetes clinic is cost-effective and has shown a reduction in visual impairment and blindness
11.30 - 11.45: Stratton, IM (UK): Retinopathy in children with diabetes: when should they be screened?
11.45 - 12.00: James, M (UK): Microcosting diabetic eye screening: estimation of personal expense, attendance and health care resource use
12.00 - 12.15: Aldington, SJ (UK): Providing the international Test and Training (iTAT) for quality assurance and training support for retinopathy screening through ‘Seeing is Believing’ projects
12.15 - 12.30: Durando, O (Italy): Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial.
12.30 - 12.45: Raj, A (UK): Oscillatory potential: A more sensitive marker for diabetic maculopathy progression?
12.45 - 1.30: Lunch and exhibition viewing (poster presenters’ priority)
1.15 - 2.45: Session 3: Poster session  
1.15 - 2.15: Poster presenters at poster – moderators will visit  
2.15 - 2.45: Tea/coffee, poster presenters circulate

Laboratory science

Ali, I (UK): Capsulotomy induced retinal degeneration in Ins2Akita mice is protected by Wnt inhibition  
Schlingemann, R: (The Netherlands): PLVAP is required for angiogenesis in vivo  
Van der Wijk, A: (The Netherlands): The development of the blood-retinal barrier as an inverse model of blood-retinal barrier loss in diseases of the retina  
Szalai, E (Hungary): Early corneal cellular and nerve fibre pathology in young patients with type 1 diabetes mellitus identified using corneal confocal microscopy  
Valverde, AM (Spain): Inhibition of protein tyrosine phosphatase 1B protects against inflammation-induced gliosis in the retina  
Ullrich, M (Austria): Exploring the pathobiology of diabetic macular oedema by post-mortem immunohistochemistry

Epidemiology

Dutra Medeiros, M (Portugal): First diabetic retinopathy prevalence study in Portugal: RETINODIAB Study—Evaluation of the screening programme for Lisbon and Tagus Valley region  
Raposo, JF (Portugal): First incidence and progression study for diabetic retinopathy in Portugal, the RETINODIAB Study evaluation of the screening program for Lisbon region

Risk factors

Derkac, I (Lithuania): The relevance of serum apolipoprotein B, apolipoprotein A1 and it’s ratio to the severity of diabetic retinopathy in type 1 diabetes mellitus  
Gahir, N (UK): Diabetic Retinopathy after initiating continuous subcutaneous insulin infusion (insulin pump)  
Schreur, V (The Netherlands): Risk factors for diabetic retinopathy in type 1 diabetes mellitus patients with poor glycaemic control

Visual function /QoL

Lopez Galvez, MI (Spain): Quality of life in patients with diabetic macular oedema and moderate to severe vision loss treated with ranibizumab in clinical practice

Screening

Harding, SP (UK): 10 year observational study of patient related outcomes during expansion to full population coverage of a systematic diabetes eye care programme – the Liverpool Diabetic Eye Study  
van der Heijden, A (The Netherlands): Validation of an algorithm to predict the risk of sight threatening retinopathy in a multi-ethnic patient group treated in a secondary care setting  
Parvizi, S (UK): Can we adopt a pragmatic approach to arterial embolus referrals from the diabetic eye screening programme?  
Moreton, RBR (UK): Factors determining patient uptake of diabetic retinopathy screening in Oxfordshire  
Palethorpe, D (UK): Evaluation of clinical and treatment outcomes of patients referred from the NHS Diabetic Eye Screening Programme  
Brown, A (UK): Characteristics and outcome of referable diabetic maculopathy  
Stewart, A (UK): The characteristics of patients referred by an English Diabetic Eye Screening Programme
Brown, A (UK): The characteristics of patients who do not attend their hospital eye clinic appointment following referral with diabetic retinopathy

Blindbæk, SL (Denmark): Predictive value of retinal venous loops in the screening for proliferative diabetic retinopathy

Thomas, R (UK): Prevalence of diabetic retinopathy in children and young persons with type 1 diabetes within the Diabetic Retinopathy Screening Service for Wales (DRSSW)

Sampson, C (UK): Health-related quality of life of people attending screening for diabetic retinopathy within a trial setting

Stratton, IM (UK): When does retinopathy have an impact on visual acuity?

Palarie, N (Moldova): First diabetic eye screening program in Moldova - 2 years results

Patra, S (UK): The risk of clinical harm due to delayed follow-up in patients with sight threatening diabetic retinopathy

Wang, A (UK): Building a dynamic functional clinical data warehouse for personalised health care - lessons from the Individualised Screening for Diabetic Retinopathy study

Staff, RT (UK): Quality assurance in diabetic retinal screening in South Africa: a baseline and follow-up study

Toth, L (UK): Visual outcomes in patients attending the surveillance and slit lamp clinic of the Tower Hamlets Diabetic Eye Screening Programme

Thetford, C (UK): Comparing health professionals’ and patient perspectives of individualised screening intervals for diabetic retinopathy screening

Automated grading:

Ribeiro, ML (Portugal): Added value of an automated analysis system in the context of Diabetic Retinopathy Screening

Hansen, M (Denmark): Automated detection of diabetic retinopathy in three European populations

Imaging

Midena, E (Italy): Hyperreflective retinal spots in diabetic eyes: the validation approach

Vujosevic, S (Italy): Diabetic macular edema with subfoveal neuroretinal detachment: Specific morphologic and functional entity

Stanga, P (UK): Vitreous segmentation of ocular coherence tomography angiography of the posterior pole and mid-periphery in diabetic retinopathy

Tomasso, L (Italy): Dynamic functionality and static changes of retinal vessels in eyes with diabetic macular edema

Benatti, L (Italy): Impact of intravitreal ranibizumab on vessel functionality in patients with diabetic macular edema

Marques, IP (Portugal): Methods for quantification of retinal microvascular density in Cirrus AngioPlex OCT Angiography (OCTA) Images

Cicinelli, MV (Italy): Morpho-functional evaluation of diabetic eyes without diabetic retinopathy

Lee Torp, T (Denmark): Retinal vascular fractal dimension as a potential marker of treatment outcome in patients with proliferative diabetic retinopathy

Corbelli, E (Italy): Assessment of foveal avascular zone in diabetic retinopathy by Optical Coherence Tomography Angiography and correlation analysis with peripheral perfusion index

Clinical management

Tsamis, E (UK): Ultra wide-field fundus fluorescein angiography – guided Pascal laser targeted retinal photocoagulation as a first treatment option for the management of proliferative and exudative vascular retinal disorders
Chwiejczak, K (UK): Barely visible yellow Pascal® laser with or without endpoint management® in treating proliferative diabetic retinopathy and diabetic macular oedema: safety and efficacy study

Bandello, F (Italy): Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy

Doğan, E (Turkey): Short term outcomes of intravitreal aflibercept on intraocular pressure

Hodzic-Hadzibegovic, D (Denmark): Nonresponders in a group of unselected diabetes patients treated with ranibizumab for diabetic macular oedema

Jasani, K (UK): 12 months outcomes of patients with diabetic macula oedema treated with Ranibizumab in a real world DGH setting presented using a novel visual method of clinical outcomes presentation.

Costa, MA (Portugal): OCT retinal thickness response after first intravitreal injection is a predictor of visual acuity response to anti-VEGF treatment of DME

Scanlon, P (UK): Real world outcomes of VEGF inhibitor injection clinics for centre involving diabetic macular oedema

Dupas, B (France): Indocyanine green-guided targeted photocoagulation of macroaneurysms in macular edema: a pilot study

Pareja-Rios, A (Spain): Clinical management of diabetic macular edema by retina specialists in clinical practice in Spain: OBSERVAR Study

Zacharaki, F (UK): Intravitreal ranibizumab for the treatment of diabetic macular oedema: real-life 12 month results

Dikci, S (Turkey): Results of intravitreal dexamethasone implant (Ozurdex®) in cases with resistant diabetic macular edema and hard exudates on the macula center

Querques, G (Italy): Assessment of the real-life usage of intravitreal dexamethasone implant in the treatment of chronic diabetic macular edema in France

Erginay, A (France): Efficacy results of 0.2 µg/day fluocinolone acetonide implant (FAc) in DME vitrectomised patients

Peto, T (UK): Subgroup analysis of the FAME trial assessing the impact of prior therapies on vision outcomes with ILUVIEN® (fluocinolone acetonide [FAc]) implant

Ba-Ali, S (Denmark): Effect of dexamethasone intravitreal implant, Ozurdex®, on diabetic macular oedema during pregnancy

**Session 4: Experimental science**

2.45 – 3.00: Hernández, C (Spain): Mediators between reactive gliosis and vascular leakage in diabetic retinopathy: a proteomic approach using human retinas

3.00 – 3.15: Klaassen, I (The Netherlands): PLVAP regulates angiogenesis through VEGFR2

3.15 – 3.30: Arroba, Al (Spain): Modulation of microglia polarization dynamics by a sp2-iminosugar derivative during diabetic retinopathy in db/db mice

3.30 - 3.45: Mazzeo, A (Italy): Different miRNA patterns in extracellular vesicles from diabetic and healthy subjects

3.45 – 4.00: Hombrebueno, JR (Northern Ireland): Targeting STAT3 for the treatment of proliferative diabetic retinopathy

4.00 - 4.15: The Eurocondor trial and beyond – Professor Rafael Simo

**4.15 – 5.00: Eva Kohner lecture: Professor Thomas W. Gardner, Professor of Ophthalmology and Visual Sciences and Molecular & Integrative Physiology, Ann Arbor, Michigan, USA**

Introduced by Professor Rafael Simo

5.00 – 5.30: Annual General Meeting

Moderator: Professor Reinier Schlingemann
Conference dinner at Manchester Museum of Science and Industry:
7.00 pm drink reception for 7.45 pm dinner

Saturday, 25th June 2015, Renold building, C15, Manchester University

Session 5: Imaging and new technologies
9.00 - 9.15: Bhaskaranand, M (USA): Study of safety and effectiveness of automated diabetic retinopathy screening system on a large set of consecutive patient visits
9.15 - 9.30: Philip, S (UK): Automated microaneurysm counts in the region temporal to the fovea associated with the severity of diabetic retinopathy
9.45 - 10.00: Papayannis, A (UK): Ultra-wide field swept-source optical coherence tomography angiography (UWF SS OCT-A) in diabetic retinopathy
10.00 - 10.15: Soares, M (Portugal): Comparison of Diabetic Retinopathy Classification using Fluorescein Angiography and Optical Coherence Tomography Angiography
10.15 - 10.30: Santos, AR (Portugal): OCT predictors for BCVA response to intravitreal anti-VEGF treatment in eyes with diabetic macular edema

10.30 - 11.15: Coffee and exhibition: Clinical poster challenges

11.15 - 11.45: Keynote lecture: Professor Andrew J. Boulton, Manchester: Type 2 diabetes – the 21st Century epidemic

Session 6: Mini symposium of OCT
12.00 - 12.15: De Clerck, E (the Netherlands): Glucose metabolism status is associated with changes in macular thickness

Debate: OCT change in early diabetic maculopathy: thicker or thinner?
12.15 - 12.30: In favour of thinning being the early sign of neurodegenerative pathway: Jakob Grauslund, Odense, Denmark
12.30 - 12.45: In favour of thickening being an early sign of neurodegenerative pathway: Paulo Stanga, Manchester, UK
12.45 - 13.00: Preliminary discussion points: Can we see distinct phenotypes? What happens with the choroid?

13.00: Best poster prize ceremony and closing remarks by Professor Simon Harding

Version 17th March 2016